| Latest Alizyme Plc News Headlines |
| Date | Time | Source | |
| 08/19/2008 | 7:36AM | UKREG | Block Listing Six Monthly Return
RNS Number : 6342B
Alizyme PLC
19 August 2008
For Immediate Release 19 August 2008
ALIZYME PLC
BLOCK LISTING SIX MONTHLY RETURN
Name of applicant: Alizyme plc
Name of scheme: The Alizyme plc 2001 Unapproved... More...>> |
| 08/15/2008 | 12:08PM | UKREG | Notification of Shares
RNS Number : 4796B
Alizyme PLC
15 August 2008
For Immediate Release 15 August 2008
ALIZYME PLC
TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are
attached:... More...>> |
| 08/15/2008 | 11:04AM | UKREG | Notification of Shares
RNS Number : 4685B
Alizyme PLC
15 August 2008
For Immediate Release 15 August 2008
ALIZYME PLC
TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
* Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Alizyme plc... More...>> |
| 07/29/2008 | 11:13AM | UKREG | Major Interest in Shares
RNS Number : 1468A
Alizyme PLC
29 July 2008
For Immediate Release 29 July 2008
ALIZYME PLC
TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are
attached:
Alizyme... More...>> |
| 07/25/2008 | 8:50AM | UKREG | Major Interest In Shares
RNS Number : 9205Z
Alizyme PLC
25 July 2008
For Immediate Release 25 June 2008
ALIZYME PLC
TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Alizyme plc
2. Reason... More...>> |
| 07/25/2008 | 3:51AM | TFNF | UK smallcap opening - Alizyme rebounds after disappointing trial results
Alizyme, hard-hit Thursday on disappointing
trial results, rebounded 0.74 of a penny to 8.50 pence as traders took the view
that there are more important drugs in the company's portfolio, including
obesity drug Cetilistat.
Acquisition news provided a spur for Biocompatibles, 3-1/4 pence firmer at
143 pence... More...>> |
| 07/24/2008 | 3:49AM | TFNF | UK smallcap opening - Alizyme drops on phase 111 trial failure
Alizyme was under pressure, dropping 26 percent
-- or 4 pence to 11-1/2 pence -- following news that the company's drug
COLAL-PRED for moderate to severe ulcerative colitis failed to meet a primary
endpoint in a phase III trial.
And Tangent Communications dipped 3/4 of a penny to 4-1/2 pence as the
company... More...>> |
| 07/24/2008 | 2:56AM | TFNF | Alizyme says COLAL-PRED drug misses key efficacy goal in phase III trials
Alizyme Plc said its COLAL-PRED ulcerative
colitis drug missed a key efficacy goal during large-scale trials and it is
holding discussions with partners to work out the best way forward.
During the European phase III trial, the drug met its safety goal but missed
its key efficacy goal of showing non-inferiority... More...>> |
| 07/24/2008 | 2:01AM | UKREG | EUROPEAN PHASE III CLINICAL TRIAL RESULTS
RNS Number : 7683Z
Alizyme PLC
24 July 2008
Please note that an Analyst meeting is being held at the offices of Buchanan Communications, 45 Moorfields, London, EC2Y 9AE at 11:00am.
A web cast will be available, to connect to the web cast facility, please go to:
http://mediaserve.buchanan.uk.com/webcasts/livegold/Irframes.htm... More...>> |
| 07/16/2008 | 9:19AM | UKREG | Major Interest in Shares
RNS Number : 2199Z
Alizyme PLC
16 July 2008
For Immediate Release 16 June 2008
ALIZYME PLC
TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
* Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Alizyme plc
2... More...>> |
| 07/01/2008 | 8:33AM | UKREG | Annual Information Update
RNS Number : 9982X
Alizyme PLC
01 July 2008
For Immediate Release 1 JULY 2008
ALIZYME PLC
ANNUAL INFORMATION UPDATE
Alizyme plc (LSE: AZM), Cambridge, UK, 1 July 2008: Alizyme Annual Information Update for the period from 1 July 2007 until 30 June
2008.
Alizyme plc ("Alizyme... More...>> |
| 06/27/2008 | 4:01AM | TFNF | Alizyme grants Norgine Colal-Pred license; deal worth up to 42.75 mln euros
Alizyme Plc. has granted Norgine B.V. an
exclusive licence for Colal-Pred, a drug used for the treatment of ulcerative
colitis.
The deal, worth up to 42.75 million euros ($67 million), gives the specialty
pharmaceutical company Norgine the right to produce and market Colal-Pred in
Europe, South Africa... More...>> |
| 06/27/2008 | 2:01AM | UKREG | ALIZYME LICENSES COLAL-PRED® TO NORGINE
RNS Number : 6733X
Alizyme PLC
27 June 2008
Immediate Release 27 June 2008
Please be aware that they will be an analyst meeting commencing at 11am at the offices of Buchanan Communications, 45 Moorfields,
London, EC2Y 9AE where Tim McCarthy, Chief Executive Officer of Alizyme and Peter Stein... More...>> |
| 06/24/2008 | 6:48AM | UKREG | Result of AGM
RNS Number : 3933X
Alizyme PLC
24 June 2008
For Immediate Release 24 JUNE 2008
ALIZYME PLC
ANNUAL GENERAL MEETING: 2008
Alizyme plc (LSE: AZM), Cambridge, UK, 24 June 2008: At the Annual General Meeting ("AGM") held today, all Resolutions 1 to 9 were duly
passed. Details... More...>> |
| 06/20/2008 | 4:02AM | UKREG | Presentation at Conference
RNS Number : 1667X
Alizyme PLC
20 June 2008
For Immediate Release 20 June 2008
Alizyme plc
ALIZYME TO PRESENT AT THE 2008 PIPER JAFFRAY EUROPE CONFERENCE
Cambridge UK, 20 June 2008: Alizyme plc (LSE: AZM) announces that Tim McCarthy, Chief Executive Officer, will be presenting... More...>> |
| 06/12/2008 | 5:00AM | UKREG | ALIZYME AT THE 2008 BIO INTERNATIONAL CONFERENCE
RNS Number : 5443W
Alizyme PLC
12 June 2008
Immediate Release 12 June 2008
ALIZYME TO PRESENT AT THE 2008 BIO International Convention
Cambridge UK, 12 June 2008: Alizyme plc (LSE: AZM) announces that Tim McCarthy, Chief Executive Officer, will be presenting at the 2008
BIO... More...>> |
| 06/09/2008 | 10:00AM | UKREG | Notification of Shares
RNS Number : 2972W
Alizyme PLC
09 June 2008
For Immediate Release 9 June 2008
ALIZYME PLC
TR * 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Alizyme plc
2. Reason... More...>> |
| 06/05/2008 | 10:31AM | UKREG | Notification of Shares
RNS Number : 0959W
Alizyme PLC
05 June 2008
For Immediate Release 6 June 2008
ALIZYME PLC
TR * 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights
are attached:
Alizyme plc... More...>> |
| 06/05/2008 | 10:31AM | UKREG | Notification of Shares
RNS Number : 0961W
Alizyme PLC
05 June 2008
For Immediate Release 5 June 2008
ALIZYME PLC
TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
* Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Alizyme plc
2... More...>> |
| 05/20/2008 | 3:33AM | TFNF | Alizyme starts phase II U.S. study for Colal-Pred ulcerative colitis treatment
Alizyme Plc. said Prometheus Laboratories Inc.,
its partner in north America for Colal-Pred, has initiated its clinical
development in the United States with a phase II study for the treatment of
ulcerative colitis.
Tim McCarthy, Alizyme's chief executive, said: "We continue with a number of
ongoing discussions... More...>> |